Pharmacovigilance – News and Features

Synthetic biology techniques have emerged as transformative tools in the tug-of-war between humans and drug-resistant bacteria. Discover how researchers are utilizing synthetic biology techniques to engineer new antimicrobials.

A novel CAR T-cell therapy has benefitted patients with relapsed acute lymphoblastic leukemia, showing high response rates in a Phase Ib/II trial.

Researchers have developed programmable DNA nanostructures using DNA origami. These customizable nanobots have vast applications, from targeted drug delivery and adaptive materials to energy-efficient optical systems.

Benralizumab, a monoclonal antibody, is the first breakthrough in asthma and COPD flare-up treatment in 50 years. Targeting eosinophilic inflammation, it reduces steroid use by 30% and lowers treatment failure rates.

Researchers revealed that checkpoint inhibitors, a powerful cancer immunotherapy, impair B cell function, reducing antibody diversity and increasing infection risk. They suggest immunoglobulin replacement therapy as a preventive measure.

Researchers developed a gene therapy to enhance placental function by delivering IGF-1 DNA using nanoparticles. Tested in rhesus macaques, the therapy improved placental health without adverse effects.

Researchers collaborated on a novel, highly specific strategy to treat type 1 diabetes using a tagged beta cell transplant in tandem with localized immune protection provided by specialized immune cells.

A wearable TENS device delivering low-voltage electrical currents significantly reduced pain and fatigue in long-COVID patients, improving mobility by 8% in fast walking tests.

A Mount Sinai team has developed a blood-brain barrier-crossing conjugate (BCC) platform, enabling therapeutic molecules to target the brain. The system effectively silenced disease-related genes like Sod1 in ALS and Mapt in Alzheimer’s.

University of Vienna researchers have developed gut-stable oxytocin analogs for chronic abdominal pain treatment. These non-opioid, oral peptides target gut-specific oxytocin receptors, minimizing side effects.